BLRX News and Press, BioLineRx Ltd. From 12/20/22

BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors PR Newswire Study Met Primary Endpoint for Safety and Tolerability First-in-Human, Single-Agent Study Demonstrated Immune Activity Across Multiple Bio...

BioLineRx to Participate in the 12th Annual LifeSci Partners Corporate Access Event PR Newswire TEL AVIV, Israel , Nov. 28, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncolo...

BioLineRx Ltd. (BLRX) Q3 2022 Earnings Conference Call November 15, 2022, 10:00 AM ET Company Participants John Lacey - IR Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Holly May - Chief Commercial Officer Abi Vainstein-Hara...

biolinerx press release ( NASDAQ: BLRX ): Q3 GAAP EPS of -$0.01. As of September 30, 2022, the Company had cash, cash equivalents, and short-term bank deposits of $57.3 million and anticipates this will be sufficient to fund operations, as currently planned, into the ...

BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates PR Newswire - Announced FDA acceptance of APHEXDA® (motixafortide) New Drug Application (NDA) in stem cell mobilization with Prescription Drug User Fee Act (PDUFA) ...

BioLineRx to Report Third Quarter 2022 Results on November 15, 2022 PR Newswire Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel , Nov. 10, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage ...

The U.S. Food and Drug Administration (FDA) accepted for review BioLineRx's ( NASDAQ: BLRX ) application seeking approval of Aphexda (motixafortide) in stem cell mobilization (SCM) for autologous transplantation in patients with multiple myeloma. The FDA is expected to...

BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization PR Newswire - PDUFA target action date set for September 9, 2023 - NDA submission based on GENESIS Phase 3 trial data that met ...

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire TEL AVIV, Israel , Nov. 4, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that...

BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society of Hematology (ASH) Annual Meeting PR Newswire Full data from pharma...